News

Filter

1 to 9 of 19 results

Bristol-Myers’ daclatasvir NDA resubmission accepted by FDA

Bristol-Myers’ daclatasvir NDA resubmission accepted by FDA

13-03-2015

US pharma major Bristol-Myers Squibb says that its resubmitted New Drug Application for daclatasvir (proposed…

Anti-viralsBiotechnologyBristol-Myers SquibbdaclatasvirDaklinzaRegulationsofosbuvirUSA

US FDA requests additional data for Bristol-Myers Squibb's daclatasvir

US FDA requests additional data for Bristol-Myers Squibb's daclatasvir

27-11-2014

US pharma major Bristol-Myers Squibb has received a Complete Response Letter from the US Food and Drug…

Anti-viralsBristol-Myers SquibbdaclatasvirPharmaceuticalRegulationUSA

Bristol-Myers reveals access plan for hep C drug daclatasvir

03-11-2014

US Pharma major Bristol-Myers Squibb has recently revealed a commercial strategy for sales of its new…

Anti-viralsBristol-Myers SquibbdaclatasvirDaklinzaMarkets & MarketingPharmaceuticalPricing

Bristol-Myers Squibb pulls NDA for combo hep C drug asunaprevir

Bristol-Myers Squibb pulls NDA for combo hep C drug asunaprevir

08-10-2014

Bristol-Myers Squibb has decided that it will not pursue US Food and Drug Administration approval of…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirGenotypeGilead SciencesMarkets & MarketingPharmaceuticalRegulationSovaldiUnited StatesUS Food and Drug AdministrationUSA

New study identifies potential alternatives to Gilead’s Sovaldi

New study identifies potential alternatives to Gilead’s Sovaldi

29-07-2014

There are multiple hepatitis treatments in development that may serve as potential alternatives to Gilead…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbdaclatasvirGilead SciencesGlobalHepatitis C treatmentMarkets & MarketingmericitabinePharmaceuticalRocheSovaldi

Bristol-Myers’ all-oral daclatasvir and asunaprevir combo shines in Ph III

Bristol-Myers’ all-oral daclatasvir and asunaprevir combo shines in Ph III

10-04-2014

US pharma major Bristol-Myers Squibb has presented new Phase III trial data of its combination therapy…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirPharmaceuticalResearch

Bristol-Myers Squibb files for US approval of daclatasvir and asunaprevir for hepatitis C

Bristol-Myers Squibb files for US approval of daclatasvir and asunaprevir for hepatitis C

07-04-2014

US pharma major Bristol-Myers Squibb has submitted New Drug Applications with the US Food and Drug Administration…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirNorth AmericaPharmaceuticalRegulationUSA

1 to 9 of 19 results

Back to top